Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline Nina TamirisaKelly K. Hunt ASO Perspectives 06 January 2022 Pages: 1489 - 1492
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial Martin R. Weiser ASO Perspectives 26 November 2021 Pages: 1493 - 1495
Too Many or Too Few? How Many Lymph Nodes Are Enough? Teviah E. Sachs Pancreatic Tumors 22 October 2021 Pages: 1496 - 1497
Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy Beth A. HelminkGeorge AnsstasRyan C. Fields Melanoma 17 November 2021 Pages: 1498 - 1501
Editorial: Impact of the Covid-19 Pandemic on Breast Cancer Treatment and Patient Experience Jill R. Dietz Breast Oncology 02 January 2022 Pages: 1502 - 1503
Communication is the Key to an Improved Patient Experience When it Comes to Surgical Delays Jill R. Dietz Breast Oncology 02 January 2022 Pages: 1504 - 1505
Removing Barriers to Access Starts with a Phone Call: Impact of Pre-Visit Coordination of Care in Efficiency of Therapy and Patient and Provider Satisfaction Andrew J. SinnamonPamela J. HodulJose M. Pimiento Gastrointestinal Oncology 01 December 2021 Pages: 1506 - 1508
The Importance of Clinical Decision-Making in Surgical Planning for Non-Small Cell Lung Cancer Hollis JohansonIkenna Okereke Thoracic Oncology 08 November 2021 Pages: 1509 - 1510
Chest CT-Derived Muscle Metrics for Sarcopenia: Choosing the Right Target Palmi ShahMark Supanich Thoracic Oncology 13 November 2021 Pages: 1511 - 1512
The Paradox of Early Stage Rectal Cancer: More ReSeARCh in the Right Direction Paolo GoffredoJ. Joshua Smith Colorectal Cancer 30 November 2021 Pages: 1513 - 1515
Cost-Effectiveness of Watch and Wait: What is in the Box of this Organ-Preservation Strategy? Rodrigo Oliva Perez Colorectal Cancer 08 January 2022 Pages: 1516 - 1517
Access to Colorectal Cancer Care for Medicaid-Insured Patients at Designated Cancer Facilities Victoria A. MarksWalter R. HsiangKevin M. Schuster ASO Research Letter 11 November 2021 Pages: 1518 - 1522
Association of Liberal Fluid Therapy for Colorectal Cancer Surgery and Long-Term Oncologic Recurrence Andres Zorrilla-VacaJavier Ripolles-MelchorAlicia Ruiz-Escobar ASO Research Letter 08 November 2021 Pages: 1523 - 1525
Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy? Tahsin M. KhanAlexander J. RossiJudy C. Boughey ASO Research Letter 20 October 2021 Pages: 1526 - 1527
Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS) Alexander J. RossiEmily A. VerbusIrene L. Wapnir ASO Research Letter 02 September 2021 Pages: 1528 - 1529
Preoperative Use of a Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer Emily A. VerbusAlexander J. RossiJulia C. Tchou ASO Research Letter 16 November 2021 Pages: 1530 - 1532
A Novel Criterion for Lymph Nodes Dissection in Distal Pancreatectomy for Ductal Adenocarcinoma: A Population Study of the US SEER Database Weishen WangZiyun ShenBaiyong Shen Pancreatic Tumors 07 October 2021 Pages: 1533 - 1539
ASO Author Reflections: Lymphadenectomy in Distal Pancreatectomy for Ductal Adenocarcinoma: How to Do Better? Weishen WangBaiyong Shen ASO Author Reflections 29 September 2021 Pages: 1540 - 1541
Landmark Series: Importance of Pancreatic Resection Margins Mihir M. ShahJashodeep DattaDavid A. Kooby Pancreatic Tumors 05 January 2022 Pages: 1542 - 1550
ASO Author Reflections: Pancreatic Resection Margins—Chasing Moons Mihir M. ShahJashodeep DattaDavid A. Kooby ASO Author Reflections 07 January 2022 Pages: 1551 - 1552
Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy Hadass RomShlomit TamirEran Sadot Pancreatic Tumors 30 October 2021 Pages: 1553 - 1563
ASO Visual Abstract: Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy Hadass RomShlomit TamirEran Sadot ASO Visual Abstract 08 January 2022 Pages: 1564 - 1565
Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis Patricia C. ConroyLucia CalthorpeMohamed A. Adam Pancreatic Tumors 01 November 2021 Pages: 1566 - 1574
ASO Author Reflections: An Objective Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy Patricia C. ConroyAdnan AlseidiMohamed A. Adam ASO Author Reflections 12 November 2021 Pages: 1575 - 1576
ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis Patricia C. ConroyLucia CalthorpeMohamed A. Adam ASO Visual Abstract 15 January 2022 Pages: 1577 - 1578
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer Roberto Alva-RuizLavanya YohanathanMark J. Truty Pancreatic Tumors Open access 01 November 2021 Pages: 1579 - 1591
ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer Roberto Alva-RuizMark J. Truty ASO Author Reflections Open access 27 October 2021 Pages: 1592 - 1593
ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer Roberto Alva-RuizLavanya YohanathanMark J. Truty ASO Visual Abstract 22 November 2021 Pages: 1594 - 1595
Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy Yuji KitahataManabu KawaiHiroki Yamaue Pancreatic Tumors 01 November 2021 Pages: 1596 - 1605
ASO Visual Abstract: Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy Yuji KitahataManabu KawaiHiroki Yamaue ASO Visual Abstract 08 November 2021 Pages: 1606 - 1607
Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry Tzu-Pin LuChien-Hui WuYu-Wen Tien Pancreatic Tumors Open access 13 November 2021 Pages: 1608 - 1615
ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients. Amrita ChattopadhyayChien-Hui WuTzu-Pin Lu ASO Author Reflections 20 November 2021 Pages: 1616 - 1617
ASO Visual Abstract: Distinct Survival Outcomes for Subgroups of Stage 3 Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology, and End Results Registry Tzu-Pin LuChien-Hui WuYu-Wen Tien ASO Visual Abstract 12 January 2022 Pages: 1618 - 1619
Merkel Cell Polyomavirus Antibody Titer Predicts Recurrence-Free Survival Aaron J. ArroyaveJames M. LewisLaura M. Enomoto Melanoma 01 December 2021 Pages: 1620 - 1626
ASO Author Reflections: The Evolving and Expanding Role of Merkel Cell Polyomavirus Antibody Titers Aaron J. ArroyaveLaura M. Enomoto ASO Author Reflections 06 January 2022 Pages: 1627 - 1628
COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States Catherine H. DavisJason HoAdam C. Berger Melanoma 19 November 2021 Pages: 1629 - 1635
ASO Visual Abstract: COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States Catherine H. DavisJason HoAdam C. Berger ASO Visual Abstract 01 January 2022 Pages: 1636 - 1636
External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort Emma H. A. StahlieMichael J. CarrAlexander C. J. van Akkooi Melanoma 23 November 2021 Pages: 1637 - 1644
ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC Emma H. A. StahlieAlexander C. J. van Akkooi ASO Author Reflections 09 January 2022 Pages: 1645 - 1646
ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort Emma H. A. StahlieMichael J. CarrAlexander C. J. van Akkooi ASO Visual Abstract 08 January 2022 Pages: 1647 - 1648
Patient Perceptions of Changes in Breast Cancer Care and Well-Being During COVID-19: A Mixed Methods Study Abigail LudwigsonVictoria HuynhSarah Tevis Breast Oncology 20 December 2021 Pages: 1649 - 1657
ASO Visual Abstract: Patient Perceptions of Changes in Breast Cancer Care and Well-Being During COVID-19: A Mixed-Methods Study Abigail LudwigsonVictoria HuynhSarah Tevis ASO Visual Abstract 16 January 2022 Pages: 1658 - 1659
Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision Alison LawsFisher KatlinTari A. King Breast Oncology 23 September 2021 Pages: 1660 - 1667
ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision Alison LawsFisher KatlinTari A. King ASO Visual Abstract 03 November 2021 Pages: 1668 - 1669
Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation Regina MatarVaradan SevilimeduMelissa Pilewskie Breast Oncology 20 October 2021 Pages: 1670 - 1679
ASO Author Reflections: Observation After a Core Biopsy Diagnosis of Classic-Type LCIS Is a Safe Standard of Practice Regina MatarMelissa Pilewskie ASO Author Reflections 23 October 2021 Pages: 1680 - 1681
ASO Visual Abstract: Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation Regina MatarVaradan SevilimeduMelissa Pilewskie ASO Visual Abstract 08 January 2022 Pages: 1682 - 1682
Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic Austin D. WilliamsCecilia ChangRichard J. Bleicher Breast Oncology 11 October 2021 Pages: 1683 - 1691
ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine Austin D. WilliamsRichard J. Bleicher ASO Author Reflections 06 January 2022 Pages: 1692 - 1693
ASO Visual Abstract: Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic Austin D. WilliamsCecilia ChangRichard J. Bleicher ASO Visual Abstract 26 October 2021 Pages: 1694 - 1694